Azamian Bobak R. 4

What Happened
Bobak R. Azamian, President & CEO and Board Chair of Tarsus Pharmaceuticals (TARS), reported three open‑market sales totaling 34,603 shares between March 17–19, 2026. The sales were: 10,972 shares @ $69.42 on 2026-03-17 ($761,676); 11,667 shares @ $68.71 on 2026-03-18 ($801,640); and 11,964 shares @ $67.00 on 2026-03-19 ($801,588). Total gross proceeds were approximately $2,364,904. These were sales (not purchases) and, per the filing, were routine sell‑to‑cover transactions to satisfy tax withholding tied to RSU vesting—not discretionary stock sales.

Key Details

• Dates & prices:
  • 2026-03-17: 10,972 shares @ $69.42 — $761,676
  • 2026-03-18: 11,667 shares @ $68.71 — $801,640
  • 2026-03-19: 11,964 shares @ $67.00 — $801,588
• Total shares sold: 34,603; total proceeds: ~$2.36M.
• Shares owned after transaction: not specified in the filing.
• Footnotes:
  • F1: Sales were mandated sell‑to‑cover to satisfy tax withholding on vested RSUs (not discretionary trades).
  • F2: Reporting person is trustee of the Bobak Azamian Living Trust (est. Apr 16, 2018) and has voting/dispositive power over these shares.
• Filing timeliness: Report filed 2026-03-19 for transactions commencing 2026-03-17; the filing does not indicate lateness.

Context
Sell‑to‑cover transactions are common when restricted stock units vest and employers require tax withholdings to be satisfied by selling a portion of the shares. Because these sales were done to cover taxes (per the filing), they generally do not signal the same management sentiment as voluntary, discretionary sales.